Kevin O'Malley

Kevin O'Malley is an experienced professional in the fields of biochemistry and biophysics, currently serving as Associate Director at Novo Nordisk since October 2022. Prior to this role, Kevin held a similar position at Forma Therapeutics from September 2021 to October 2022, where responsibilities included managing biochemical, biophysical, and structural platforms for various programs. Kevin's extensive background includes nearly two decades at BMS, where the role of Principal Scientist involved the assessment of high-throughput screening hits and external leads through biophysical and biochemical methods. Kevin began the career as a Research Investigator and holds a Doctor of Philosophy in Biological Chemistry from the University of Pennsylvania.